evidencegaps
Primary study · included by 1 review

A pilot study of camrelizumab with docetaxel and cisplatin for the first line treatment in recurrent/metastatic oral squamous cell carcinoma.

Ju 2023 · Ju Houyu, Wei Dongliang, Wu Yunteng, et al. · MedComm · 2023

Included by

Two-year follow-up outcomes of neoadjuvant therapy in oral squamous cell carcinoma: an exploratory systematic review and meta-analysis.
Non-Cochrane · prognostic · 2026 · cited as Ju 2023 · Reference list 25-34; Table 1; Fig 4-8

The review does not say which of its outcomes this study informs.

1 including review in total.